微生物学
鲍曼不动杆菌
抗生素
铜绿假单胞菌
阴沟肠杆菌
金黄色葡萄球菌
屎肠球菌
肠球菌
肺炎克雷伯菌
环丙沙星
抗生素耐药性
生物
万古霉素
细菌
大肠杆菌
基因
生物化学
遗传学
作者
Daniel Pletzer,Sarah Mansour,Robert E. W. Hancock
出处
期刊:PLOS Pathogens
[Public Library of Science]
日期:2018-06-21
卷期号:14 (6): e1007084-e1007084
被引量:197
标识
DOI:10.1371/journal.ppat.1007084
摘要
With the antibiotic development pipeline running dry, many fear that we might soon run out of treatment options. High-density infections are particularly difficult to treat due to their adaptive multidrug-resistance and currently there are no therapies that adequately address this important issue. Here, a large-scale in vivo study was performed to enhance the activity of antibiotics to treat high-density infections caused by multidrug-resistant Gram-positive and Gram-negative bacteria. It was shown that synthetic peptides can be used in conjunction with the antibiotics ciprofloxacin, meropenem, erythromycin, gentamicin, and vancomycin to improve the treatment outcome of murine cutaneous abscesses caused by clinical hard-to-treat pathogens including all ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter cloacae) pathogens and Escherichia coli. Promisingly, combination treatment often showed synergistic effects that significantly reduced abscess sizes and/or improved clearance of bacterial isolates from the infection site, regardless of the antibiotic mode of action. In vitro data suggest that the mechanisms of peptide action in vivo include enhancement of antibiotic penetration and potential disruption of the stringent stress response.
科研通智能强力驱动
Strongly Powered by AbleSci AI